Yervoy footer

According to Jorge Nieva, MD, taletrectinib may be a primary frontline therapy option for those with ROS1-positive non–small cell lung cancer.

The confirmed objective response rate among 56 patients with extensive-stage small cell lung cancer was 87.5%, all of whom experienced partial responses.

A group of clinicians gives study advice on how to best prepare for the medical oncology board examinations.

Heather McArthur, MD, focused on current and future strategies for treating early-stage breast cancer.

Among 115 patients treated with avutometinib and defactinib, only 5 deaths occurred in the study, none of which were related to study treatment.